Rumi Scientific
- Company typePrivate
- Founded2016
- HeadquartersNew York, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Rumi Scientific firmographics
Firmographics- Name
- Rumi Scientific
- Legal name
- Rumi Scientific, Inc.
- Website
- https://rumiscientific.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Rumi Scientific industry classification
Industry- Product category
- Drug Discovery Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
- SIC
- Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), In Vivo Discovery & Translational Models Platforms (humanized models, PK/PD, efficacy) (HLAAAIAK), CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)
Keywords
Where Rumi Scientific is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Rumi Scientific business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Revenue model
- Therapeutic Development and Licensing: Pre-revenue biotech company focused on developing novel therapeutics for rare and neurodegenerative diseases through internal R&D programs. Revenue will be generated through licensing deals, partnerships, or eventual commercialization of drug candidates.
- SBIR Grants and Non-Dilutive Funding: The company has received $1.9 million Phase II SBIR grant from National Institutes of Mental Health to support autism and neurological disease research.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Rumi Scientific product offering
Product offeringCore offering
Rumi Scientific develops and applies a high-throughput organoid phenotypic screening platform for drug discovery in neurological and kidney diseases, combining human stem cell biology with proprietary micropattern technology and AI-driven analysis. The company also advances an internal pipeline of therapeutic candidates, led by a BRD9 inhibitor for Huntington's disease, with the intent of licensing or partnering these programs with pharmaceutical companies.
Product overview
Rumi Scientific operates as a multi-platform biotech company offering organoid-based drug discovery services centered on three proprietary platforms: Neuroloid (neural organoids for early brain development), Cerebroid (cerebral organoids for advanced brain modeling), and Nephroid (kidney organoids for renal disease). These platforms leverage AI-driven phenotypic analysis to identify therapeutic candidates. The company's therapeutic pipeline includes programs in Huntington's disease (lead BRD9 inhibitor), autism spectrum disorders (ADNP, SHANK3-targeted programs), and nephrology indications (Alport syndrome, polycystic kidney disease).
Differentiator
Problem solved
Functional benefit
Products and services
- Neuroloid Platform
- Cerebroid Platform
- Nephroid Platform
- BRD9 Inhibitor (Huntington's disease therapeutic candidate)
- Drug Discovery Collaboration Services
Quantifiable outcome
- Deep learning analysis achieved extremely high accuracy in distinguishing disease and wild-type phenotypes in complex tissues
- +2 more outcomes
Companies that use Rumi Scientific
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles2 records
Rumi Scientific technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature7 records
Rumi Scientific partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Mount Sinai - Seaver Autism Center for Research and TreatmentcoreCollaboration to develop drug discovery pipeline for rare genetic disorders tied to autism. Initial project involves development of brain tissue mimicking platform using iPSCs for three autism genes (ADNP, DDX3X, and FOXP1) to identify phenotypic signatures and screen therapeutic compounds.
- The Rockefeller UniversitycoreLicensed foundational technology from Rockefeller University for organoid platform development. The Brivanlou Laboratory and Eric Siggia collaboration laid groundwork for Rumi's transformative technology based on human embryonic stem cell work.
Scale indicators4 records
Recent moves7 records
Expansion highlights5 records
Rumi Scientific competitors and assessment
Company assessmentDirect peers
- InSphero: 3D organoid and spheroid-based drug discovery platform provider serving pharma, comparable to Rumi's high-throughput organoid screening model, including kidney and other tissue models.
- Mimetas: Organ-on-a-chip and organoid screening company providing standardized human tissue models for drug discovery, competing in similar preclinical translational workflows.
- Organoid Therapeutics: Develops organoid-based drug discovery and therapeutic platforms, including CNS-focused programs, with a similar translational research model aimed at rare genetic neurological disorders.
- StemoniX (acquired by Vyant Bio): Developed standardized iPSC-derived neural organoids and high-content screening platforms for CNS drug discovery, closely matching Rumi's micropattern/AI-driven phenotypic screening thesis.
- BrainXell: Specializes in iPSC-derived neural cells and neural disease modeling for drug discovery, directly overlapping with Rumi's Neuroloid/Cerebroid platforms in CNS phenotypic screening.
- Neurona Therapeutics: Stem-cell-derived neuronal cell therapy company for neurological diseases, sharing Rumi's stem-cell biology foundation and CNS therapeutic focus, though operating at a more advanced clinical stage.
- Cajal Neuroscience: Neuroscience-focused drug discovery company combining human stem-cell models and genetics; previously led by Ignacio Muñoz-Sanjuán (now Rumi's CEO), making it a tightly comparable neuro platform peer.
Broad incumbents
- Emulate: Larger organ-chip platform company with broader organ coverage and pharma partnerships; competes with Rumi in standardized human-model-based drug discovery but across many more tissues.
Emerging players
- CHARM Therapeutics: AI-driven 3D-structure-based drug discovery company with emerging CNS programs, comparable to Rumi's AI/biotech convergence approach in neurological drug discovery.
Others
- CHDI Foundation: Non-profit funder and convener of Huntington's disease drug discovery; Rumi's CEO Muñoz-Sanjuán previously led translational biology at CHDI, making it a relevant ecosystem participant and potential partner/funder.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Rumi Scientific social profiles
Digital presenceRumi Scientific financial estimates
Financial estimateRevenue estimate
Valuation estimate
Rumi Scientific leadership team
Management profileNumber of profiles
Profiles15 records
Rumi Scientific funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Rumi Scientific M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Rumi Scientific
What does Rumi Scientific do?
Rumi Scientific develops and applies a high-throughput organoid phenotypic screening platform for drug discovery in neurological and kidney diseases, combining human stem cell biology with proprietary micropattern technology and AI-driven analysis. The company also advances an internal pipeline of therapeutic candidates, led by a BRD9 inhibitor for Huntington's disease, with the intent of licensing or partnering these programs with pharmaceutical companies.
Is Rumi Scientific a public or private company?
Rumi Scientific is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Rumi Scientific founded?
Rumi Scientific was founded in 2016. It employs 1 to 10 people.
Where is Rumi Scientific based?
Rumi Scientific is headquartered in New York, United States, in the North America region.
How does Rumi Scientific make money?
Two revenue lines are on record. Therapeutic Development and Licensing is the primary driver. The others are SBIR Grants and Non-Dilutive Funding.
Who are Rumi Scientific's main competitors?
Direct peers on record are InSphero, Mimetas, Organoid Therapeutics, StemoniX (acquired by Vyant Bio), BrainXell, Neurona Therapeutics and Cajal Neuroscience. Emulate is listed as a broad incumbent. CHARM Therapeutics is listed as an emerging player. CHDI Foundation is listed as an others.
Does Rumi Scientific have an API?
No public API is recorded for Rumi Scientific.
What industry is Rumi Scientific in?
Rumi Scientific's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems), with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.